Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
K MrózekC D Bloomfield

Abstract

To prospectively compare cytogenetics and reverse transcriptase-polymerase chain reaction (RT-PCR) for detection of t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22), aberrations characteristic of core-binding factor (CBF) acute myeloid leukemia (AML), in 284 adults newly diagnosed with primary AML. Cytogenetic analyses were performed at local laboratories, with results reviewed centrally. RT-PCR for AML1/ETO and CBFbeta/MYH11 was performed centrally. CBF AML was ultimately identified in 48 patients: 21 had t(8;21) or its variant and AML1/ETO, and 27 had inv(16)/t(16;16), CBFbeta/MYH11, or both. Initial cytogenetic and RT-PCR analyses correctly classified 95.7% and 96.1% of patients, respectively (P =.83). Initial cytogenetic results were considered to be false-negative in three AML1/ETO-positive patients with unique variants of t(8;21), and in three CBFbeta/MYH11-positive patients with, respectively, an isolated +22; del(16)(q22),+22; and a normal karyotype. The latter three patients were later confirmed to have inv(16)/t(16;16) cytogenetically. Only one of 124 patients reported initially as cytogenetically normal was ultimately RT-PCR-positive. There was no false-positive cytogenetic result. Initial RT-PCR was falsely ne...Continue Reading

References

Jul 26, 1996·Science·E SchröckT Ried
Oct 1, 1996·Genome Research·C A HeidP M Williams
Oct 1, 1996·Genome Research·U E GibsonP M Williams
May 23, 1998·Genes, Chromosomes & Cancer·J DierlammA Hagemeijer
Jan 14, 1999·Genes, Chromosomes & Cancer·S TaviauxM Lafage-Pochitaloff
Aug 5, 1999·Cancer Genetics and Cytogenetics·C J HarrisonE Macintyre
Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Oct 12, 1999·Leukemia·S M HackwellF M Ross
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F MorschhauserC Preudhomme

❮ Previous
Next ❯

Citations

Aug 5, 2003·Current Oncology Reports·John A Liu Yin, Lindsay Frost
Dec 18, 2004·Current Opinion in Hematology·Guido MarcucciClara D Bloomfield
Jul 24, 2008·Journal of the National Cancer Institute. Monographs·Krzysztof Mrózek, Clara D Bloomfield
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas NeubauerClara D Bloomfield
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine von NeuhoffUrsula Creutzig
Aug 5, 2014·American Journal of Hematology·Melhem SolhCelalettin Ustun
Feb 14, 2019·Annals of Hematology·Ho-Jin ShinUNKNOWN Korean Society of Hematology AML/MDS Working Party
Jan 16, 2002·Current Opinion in Oncology·Louise KellyD Gary Gilliland
Dec 23, 2010·Future Oncology·Etienne De BraekeleerMarc De Braekeleer
Oct 9, 2008·Current Opinion in Oncology·Krzysztof MrózekClara D Bloomfield
Oct 23, 2010·Genes, Chromosomes & Cancer·Frank G RückerKonstanze Döhner
Sep 15, 2017·Hematological Oncology·Nathalie Douet-GuilbertMarc De Braekeleer
Jul 31, 2008·International Journal of Laboratory Hematology·S PakakasamaS Hongeng
Nov 12, 2014·Genetic Testing and Molecular Biomarkers·Yingxi HuWanping Sun
Nov 18, 2010·Expert Review of Molecular Diagnostics·Christopher D Watt, Adam Bagg
Feb 18, 2016·Stem Cells International·Federico Mosna, Michele Gottardi
Jan 31, 2015·Current Opinion in Hematology·Celalettin Ustun, Guido Marcucci
Nov 1, 2007·Clinical and Experimental Medicine·F Iffet SahinH Ozdogu
May 18, 2013·British Journal of Haematology·Jane E A GordonJohn E J Rasko
Sep 20, 2002·Blood·James W VardimanRichard D Brunning
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Clara D BloomfieldMichael A Caligiuri
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingUNKNOWN Acute Myeloid Leukemia Study Group, Ulm
Jun 9, 2004·Critical Reviews in Oncology/hematology·Matthew SmithWolfgang Kern
Dec 5, 2009·The Journal of Molecular Diagnostics : JMD·Margaret L GulleyYuri Fedoriw

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.